Ligand to Participate in March Investor Conferences

Ligand (Nasdaq: LGND) said senior management will attend three investor conferences in March 2026, offering one-on-one meetings and two public presentations.

Rhea-AI Summary

Ligand (Nasdaq: LGND) said senior management will attend three investor conferences in March 2026, offering one-on-one meetings and two public presentations. Presentations are scheduled at the 38th Annual ROTH Conference on March 23, 2026 at 1:00 p.m. PT and the Nordic-American Healthcare Conference on March 25, 2026 at 3:45 p.m. ET. Investors may request one-on-one meetings through their Leerink, ROTH, or NAHC representative.

Argus Mar 4 session

+2.31% close to close Open Argus

Details

News Market Reaction – LGND

In the Mar 4 session, LGND gained 2.31%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement outlines Ligand’s upcoming presence at several March investor conferences, emphasi...

Analysis

This announcement outlines Ligand’s upcoming presence at several March investor conferences, emphasizing continued outreach through presentations and one-on-one meetings. Recent history shows the company pairing active investor communication with strong reported financials and reiterated guidance. While today’s news does not introduce new revenue or clinical data, investors may watch for any incremental commentary from these events and compare it against prior disclosures and guidance trajectories highlighted in recent earnings and Investor Day materials.

Key Figures

Leerink conference meetings date: March 11, 2026 ROTH presentation time: 1:00 p.m. PT ROTH presentation date: March 23, 2026 +2 more

Leerink conference meetings date

March 11, 2026

One-on-one meetings at Leerink Partners Global Healthcare Conference

ROTH presentation time

1:00 p.m. PT

Presentation at 38th Annual ROTH Conference on March 23, 2026

ROTH presentation date

March 23, 2026

Management presentation at ROTH investor conference

NAHC presentation time

3:45 p.m. ET

Presentation at Nordic-American Healthcare Conference 2026

NAHC presentation date

March 25, 2026

Management presentation at Nordic-American Healthcare Conference 2026

Historical Context

5 past events · Latest: Feb 26

5 events

1. Feb 26

   Earnings results

   24h Move

   +2.5%

   Reported strong Q4 and 2025 results with royalty growth and reaffirmed 2026 guidance.

2. Feb 12

   Earnings date notice

   24h Move

   -2.3%

   Announced timing and access details for upcoming Q4 and full-year 2025 results call.

3. Feb 04

   Conference participation

   24h Move

   -0.3%

   Management scheduled for virtual fireside chat and one-on-one investor meetings.

4. Dec 09

   Investor day, guidance

   24h Move

   +0.6%

   Hosted Investor Day, introduced 2026 guidance and multi-year royalty growth outlook.

5. Nov 06

   Earnings, guidance raise

   24h Move

   +9.4%

   Reported strong Q3 2025, raised 2025 core revenue and EPS guidance, detailed royalty gains.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JUPITER, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences:

• Leerink Partners Global Healthcare Conference (Miami): Management will participate in one-on-one meetings March 11, 2026
  
  
• 38^th Annual ROTH Conference (Dana Point, Calif.): Management will present at 1:00 p.m. PT on March 23, 2026
  
  
• Nordic-American Healthcare Conference 2026 (New York): Management will present at 3:45 p.m. ET on March 25, 2026
  
  

Ligand management is scheduled to host one-on-one meetings with investors and attendees during these conferences. Investors interested in arranging one-on-one meetings should contact their Leerink, ROTH, or NAHC representative.

About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model is based on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to attempt to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty generating technology IP platform technologies. Our Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL™ platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter International. For more information, please visit www.ligand.com. Follow Ligand on X and LinkedIn.

We use our investor relations website and X as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our website and our X account, in addition to following our press releases, SEC filings, public conference calls and webcasts.

Contacts
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761

Media:
Kellie Walsh
media@ligand.com
(914) 315-6072

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Ligand (LGND) present at the 38th Annual ROTH Conference in March 2026?

Ligand will present at the 38th Annual ROTH Conference on March 23, 2026 at 1:00 p.m. PT. According to Ligand, senior management will deliver a public presentation and be available for investor one-on-one meetings arranged through ROTH representatives.

What is Ligand's (LGND) schedule for the Nordic-American Healthcare Conference in March 2026?

Ligand management will present at the Nordic-American Healthcare Conference on March 25, 2026 at 3:45 p.m. ET. According to Ligand, the team will also host one-on-one investor meetings during the conference via NAHC representatives.

How can investors arrange one-on-one meetings with Ligand (LGND) management in March 2026?

Investors should contact their Leerink, ROTH, or NAHC representative to arrange one-on-one meetings. According to Ligand, management is scheduling private investor meetings at the listed March 2026 conferences and will coordinate through those conference teams.

Which March 2026 conferences will Ligand (LGND) management attend and present at?

Ligand management will attend Leerink Partners Global Healthcare, the 38th Annual ROTH Conference, and the Nordic-American Healthcare Conference in March 2026. According to Ligand, public presentations occur March 23 and March 25, with Leerink meetings by appointment on March 11.

Will Ligand (LGND) hold presentations and one-on-one meetings at the Leerink Partners Global Healthcare Conference?

At the Leerink Partners Global Healthcare Conference, Ligand expects management to participate in one-on-one meetings on March 11, 2026. According to Ligand, those sessions are private and investors should coordinate scheduling through Leerink representatives.